Viking Therapeutics

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The firm's clinical program, VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in the development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Viking Therapeutics reports solid financials and advances in clinical programs

Viking Therapeutics showcased a strong financial position and progress in clinical programs for various disorders
Challenges include observing full efficacy in short studies and balancing efficacy with safety in dose decisions
Opportunities lie in achieving target efficacy ranges, optimizing dosing based on data, and releasing comprehensive study results

Viking Therapeutics reports Q1 progress and financial stability post-offering

Viking Therapeutics showcased progress in clinical programs and financial stability post-public offering.
Analyst inquiries focused on tolerability, dosing, and expectations for top-line results of key compounds.
Challenges include managing expenses, PK/PD profile comparisons, and uncertainties in enrollment for upcoming studies.
Opportunities lie in pipeline expansions, confidence in oral formulation data, and potential combination studies for future growth.

Viking Therapeutics excels in clinical trials and financial stability

Viking Therapeutics delivered strong clinical and financial performance in Q2 2023, positioning itself well in the NASH and obesity markets.
The company's methodical approach to clinical trials and focus on internal development underscore a strategic and disciplined growth strategy.
While facing financial challenges and operational complexities, Viking has opportunities to leverage positive trial results and cash reserves for future growth.
Overall, Viking's Q2 performance reflects a balanced pursuit of innovation, financial prudence, and strategic advancement in its pipeline.

Viking Therapeutics reports robust Q3 performance and eyes combination therapies

Viking Therapeutics showcased strong clinical data and financial stability in Q3 2023, with key trials progressing as planned.
While facing challenges like limited MRI data and formulation complexities, the company's commitment to innovation and scalability remains evident.
Opportunities lie in exploring combination therapies, addressing patient preferences, and leveraging market trends for future growth.
Overall, Viking's performance, strengths, and strategic outlook position them well for continued success in the biopharmaceutical sector.

Viking Therapeutics excels in clinical trials and financial growth

Viking Therapeutics showcased positive trial results, financial strength, and a proactive approach to advancing their pipeline. While facing challenges in managing expenses and navigating regulatory requirements, the company remains optimistic about the potential of their clinical programs. Opportunities for growth exist through successful trial outcomes, strategic partnerships, and regulatory engagements.

Viking Therapeutics reports strong Q1 results and plans pipeline expansion

Viking Therapeutics showcased positive clinical outcomes for VK2735 and VK2809, supported by a successful public offering.
Financially, the company reported increased expenses but maintains a robust cash position for future development.
Challenges include managing expenses, regulatory transitions, and data reporting timelines, while opportunities lie in market expansion and regulatory advancements.
Overall, Viking's strategic focus on pipeline advancement and leveraging strong financials positions them for continued growth and success.

Viking Therapeutics advances breakthrough therapies with strong financial backing

Viking Therapeutics reported positive trial outcomes and a strong financial position, poised to advance breakthrough therapies for obesity and NASH.
While facing regulatory and financial challenges, Viking's innovative approach and diverse pipeline present opportunities for growth and strategic partnerships.
With a focus on advancing Phase III programs and exploring new treatment avenues, Viking remains well-positioned to drive therapeutic innovation and address unmet medical needs.

Viking Therapeutics excels in clinical trials and strategic partnerships

Viking Therapeutics delivered strong clinical progress and financial stability in Q3 2024, positioning itself for further growth and development. While facing cost challenges, the company is actively pursuing strategic opportunities to advance its pipeline and expand its market presence.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Akcea Therapeutics

AMAG Pharmaceuticals

Axsome Therapeutics

Cronos Group

Eidos Therapeutics Inc

Heron Therapeutics

Ligand Pharmaceuticals

Paratek Pharma

PolarityTE Inc

Intrexon

ZIOPHARM Oncology

Biotech investment is risk fraught. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts.

12 Biotech Stocks Primed For A Short Squeeze

I'm Picking Viking Therapeutics For NASH

Can the stock march even higher after its recent rally?

Up 19.2%, Is Viking Therapeutics Stock Still a Buy?

The biotech's Q3 update fired up investors.

Why Viking Therapeutics Stock Soared Today

Viking Therapeutics, Inc. (VKTX) CEO Brian Lian on Q3 2019 Results - Earnings Call Transcript

Callon Petroleum

Galmed Pharmaceuticals

Sientra

Tellurian

While most of Wall Street focuses on large and mega cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Healthy Upside Potential Seen in 5 More Stocks Trading Under $10

Intercept Pharma

The biotech rivals each aim to dominate the treatment market for non-alcoholic steatohepatitis (NASH).

Better Buy: Intercept Pharmaceuticals vs. Viking Therapeutics

VKTX produced strong data in reducing liver fat in NAFLD patients.

Viking Therapeutics: A Potential NASH Blockbuster

MannKind

Moderna

This has been a hard year for biotech. It seems that both Democrats and Republicans are wanting to target drug prices, and fears of universal health care in the years ahead would mean lower profitability for the sector as a whole.

8 Biotechs Being Choked by Short Sellers

What you need to know about this high-risk, high-reward biotech stock.

Is Viking Therapeutics a Buy?

It's one of the more promising companies in the race to develop a successful NASH treatment. Will patient investors be rewarded?

Where Will Viking Therapeutics Be in 1 Year?

Viking Therapeutics' (VKTX) CEO Brian Lian on Q2 2019 Results - Earnings Call Transcript

Philip Morris

Welltower

The catalysts these companies enjoy could translate into big returns for shareholders in the coming decades.

Three Stocks to Buy and Hold for the Next 50 Years

Cara Therapeutics

Editas Medicine

They're risky. You'll have to wait years before any significant revenue comes in.

3 Small-Cap Biotech Stocks You Can Buy Right Now

Viking Therapeutics, Inc. (VKTX) CEO Brian Lian on Q1 2019 Results - Earnings Call Transcript

Viking's shares received a boost from a pair of catalysts last month.

Why Viking Therapeutics Stock Perked Up in March

TherapeuticsMD

Are intrepid short-sellers taking advantage of misguided enthusiasm?

Here's Why Investors Are Betting Against These 2 Biotech Stocks

XPO Logistics

Bargain hunting? These out-of-favor biotech and e-commerce stocks should appeal to value investors.

Value Stocks to Buy Right Now

Investors were impressed with updated results for the company's lead candidate.

Here's What Pushed Viking Therapeutics Higher on Friday

Inovio Pharmaceuticals

La Jolla Pharmaceutical

This off-the radar pick could be poised to be a huge winner. Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is a clinical-stage biopharmaceutical company.

5 Sizzling Biotech Stocks Under $10 With Gigantic Upside Potential

Viking Therapeutics, Inc. (VKTX) CEO Brian Lian on Q4 2018 Results - Earnings Call Transcript

Nektar Therapeutics

Here's why Wall Street thinks these stocks could generate returns of 100% or more in the next 12 months.

News for Viking Therapeutics Stock (VKTX)